Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region
Leah G Jarsberg, Komal Kedia, Jason Wendler, Aaron T Wright, Paul D Piehowski, Marina A Gritsenko, Tujin Shi, David M Lewinsohn, George B Sigal, Marc H Weiner, Richard D Smith, Joseph Keane, Jon M Jacobs, Payam Nahid, Leah G Jarsberg, Komal Kedia, Jason Wendler, Aaron T Wright, Paul D Piehowski, Marina A Gritsenko, Tujin Shi, David M Lewinsohn, George B Sigal, Marc H Weiner, Richard D Smith, Joseph Keane, Jon M Jacobs, Payam Nahid
Abstract
Introduction: Contemporary phase 2 TB disease treatment clinical trials have found that microbiologic treatment responses differ between African versus non-African regions, the reasons for which remain unclear. Understanding host and disease phenotypes that may vary by region is important for optimizing curative treatments.
Methods: We characterized clinical features and the serum proteome of phase 2 TB clinical trial participants undergoing treatment for smear positive, culture-confirmed TB, comparing host serum protein expression in clinical trial participants enrolled in African and Non-African regions. Serum samples were collected from 289 participants enrolled in the Centers for Disease Control and Prevention TBTC Study 29 (NCT00694629) at time of enrollment and at the end of the intensive phase (after 40 doses of TB treatment).
Results: After a peptide level proteome analysis utilizing a unique liquid chromatography IM-MS platform (LC-IM-MS) and subsequent statistical analysis, a total of 183 core proteins demonstrated significant differences at both baseline and at week 8 timepoints between participants enrolled from African and non-African regions. The majority of the differentially expressed proteins were upregulated in participants from the African region, and included acute phase proteins, mediators of inflammation, as well as coagulation and complement pathways. Downregulated proteins in the African population were primarily linked to nutritional status and lipid metabolism pathways.
Conclusions: We have identified differentially expressed nutrition and lipid pathway proteins by geographic region in TB patients undergoing treatment for pulmonary tuberculosis, which appear to be associated with differential treatment responses. Future TB clinical trials should collect expanded measures of nutritional status and further evaluate the relationship between nutrition and microbiologic treatment response.
Conflict of interest statement
The authors declare no competing interests in regard any relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, including those authors currently affiliated with Merck & Co Inc. and Meso Scale Diagnostics.
Figures
References
- Chaisson RE, Martinson NA. Tuberculosis in Africa—Combating an HIV-Driven Crisis. New England Journal of Medicine. 2008;358(11):1089–92. 10.1056/NEJMp0800809 .
- Chatterjee D, Pramanik AK. Tuberculosis in the African continent: A comprehensive review. Pathophysiology. 2015;22(1):73–83. 10.1016/j.pathophys.2014.12.005
- Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, et al.. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015;191(3):333–43. 10.1164/rccm.201410-1843OC
- Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, et al.. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012;206(7):1030–40. 10.1093/infdis/jis461 .
- Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al.. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009;180(3):273–80. 10.1164/rccm.200901-0078OC .
- Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et al.. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174(3):331–8. Epub 2006/05/06. 10.1164/rccm.200603-360OC .
- Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, et al.. Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One. 2011;6(4):e18358. 10.1371/journal.pone.0018358
- Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, et al.. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2010;5(5):e10753. 10.1371/journal.pone.0010753
- Kedia K, Wendler JP, Baker ES, Burnum-Johnson KE, Jarsberg LG, Stratton KG, et al.. Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis. Tuberculosis. 2018;112:52–61. 10.1016/j.tube.2018.07.005
- Baker ES, Burnum-Johnson KE, Jacobs JM, Diamond DL, Brown RN, Ibrahim YM, et al.. Advancing the High Throughput Identification of Liver Fibrosis Protein Signatures Using Multiplexed Ion Mobility Spectrometry. Molecular & Cellular Proteomics: MCP. 2014;13(4):1119–27. 10.1074/mcp.M113.034595
- Shi T, Sun X, Gao Y, Fillmore TL, Schepmoes AA, Zhao R, et al.. Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. Journal of proteome research. 2013;12(7):3353–61. 10.1021/pr400178v
- Nielson CM, Jones KS, Chun RF, Jacobs JM, Wang Y, Hewison M, et al.. Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations. J Clin Endocrinol Metab. 2016;101(5):2226–34. 10.1210/jc.2016-1104
- MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al.. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966–8. 10.1093/bioinformatics/btq054
- He J, Sun X, Shi T, Schepmoes AA, Fillmore TL, Petyuk VA, et al.. Antibody‐independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer. Molecular Oncology. 2014;8(7):1169–80. 10.1016/j.molonc.2014.02.004
- Polpitiya AD, Qian WJ, Jaitly N, Petyuk VA, Adkins JN, Camp DG 2nd, et al.. DAnTE: a statistical tool for quantitative analysis of -omics data. Bioinformatics. 2008;24(13):1556–8. Epub 2008/05/06. 10.1093/bioinformatics/btn217
- Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D, et al.. Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation. J Lipid Res. 1991;32(12):1919–28. Epub 1991/12/01. .
- Cobbaert C, Mulder P, Lindemans J, Kesteloot H. Serum LP(a) levels in African aboriginal Pygmies and Bantus, compared with Caucasian and Asian population samples. J Clin Epidemiol. 1997;50(9):1045–53. Epub 1997/11/18. 10.1016/s0895-4356(97)00129-7 .
- Schmidt K, Kraft HG, Parson W, Utermann G. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. Eur J Hum Genet. 2006;14(2):190–201. Epub 2005/11/04. 10.1038/sj.ejhg.5201512 .
- Thomson R, Finkelstein A. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. Proc Natl Acad Sci U S A. 2015;112(9):2894–9. Epub 2015/03/03. 10.1073/pnas.1421953112
- Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, et al.. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003;422(6927):83–7. Epub 2003/03/07. 10.1038/nature01461 .
- Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al.. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–5. Epub 2010/07/22. 10.1126/science.1193032
- Aldred AR, Schreiber G. The negative acute phase proteins. In: Mackiewicz A, Kushner I, Bauman H, editors. Acute Phase Proteins Molecular Biology, Biochemistry, and Clinical Applications. Boca Raton, FL.: CRC Press; 1993. p. 21–37.
- Blomhoff R, Green MH, Green JB, Berg T, Norum KR. Vitamin A metabolism: new perspectives on absorption, transport, and storage. Physiol Rev. 1991;71(4):951–90. Epub 1991/10/01. 10.1152/physrev.1991.71.4.951 .
- Rosales FJ, Ross AC. Acute inflammation induces hyporetinemia and modifies the plasma and tissue response to vitamin A supplementation in marginally vitamin A-deficient rats. J Nutr. 1998;128(6):960–6. Epub 1998/06/18. 10.1093/jn/128.6.960 .
- Rosales FJ, Ross AC. A low molar ratio of retinol binding protein to transthyretin indicates vitamin A deficiency during inflammation: studies in rats and a posterior analysis of vitamin A-supplemented children with measles. J Nutr. 1998;128(10):1681–7. Epub 1998/10/15. 10.1093/jn/128.10.1681 .
- Hatsuda K, Takeuchi M, Ogata K, Sasaki Y, Kagawa T, Nakatsuji H, et al.. The impact of nutritional state on the duration of sputum positivity of Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2015;19(11):1369–75. Epub 2015/10/16. 10.5588/ijtld.14.0963 .
- Podewils LJ, Holtz T, Riekstina V, Skripconoka V, Zarovska E, Kirvelaite G, et al.. Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients. Epidemiol Infect. 2011;139(1):113–20. Epub 2010/05/01. 10.1017/S0950268810000907 .
- Bhargava A, Chatterjee M, Jain Y, Chatterjee B, Kataria A, Bhargava M, et al.. Nutritional status of adult patients with pulmonary tuberculosis in rural central India and its association with mortality. PLoS One. 2013;8(10):e77979. Epub 2013/11/10. 10.1371/journal.pone.0077979
- Khan A, Sterling TR, Reves R, Vernon A, Horsburgh CR. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med. 2006;174(3):344–8. Epub 2006/05/20. 10.1164/rccm.200511-1834OC .
- Calder PC, Jackson AA. Undernutrition, infection and immune function. Nutr Res Rev. 2000;13(1):3–29. Epub 2000/06/01. 10.1079/095442200108728981 .
- Hood ML. A narrative review of recent progress in understanding the relationship between tuberculosis and protein energy malnutrition. Eur J Clin Nutr. 2013;67(11):1122–8. Epub 2013/08/15. 10.1038/ejcn.2013.143 .
- Baazim H, Schweiger M, Moschinger M, Xu H, Scherer T, Popa A, et al.. CD8(+) T cells induce cachexia during chronic viral infection. Nat Immunol. 2019;20(6):701–10. Epub 2019/05/22. 10.1038/s41590-019-0397-y
- Polasa K, Murthy KJ, Krishnaswamy K. Rifampicin kinetics in undernutrition. Br J Clin Pharmacol. 1984;17(4):481–4. Epub 1984/04/01. 10.1111/j.1365-2125.1984.tb02377.x
- van Lettow M, van der Meer JW, West CE, van Crevel R, Semba RD. Interleukin-6 and human immunodeficiency virus load, but not plasma leptin concentration, predict anorexia and wasting in adults with pulmonary tuberculosis in Malawi. J Clin Endocrinol Metab. 2005;90(8):4771–6. Epub 2005/06/02. 10.1210/jc.2004-2539 .
- Macallan DC, McNurlan MA, Kurpad AV, de Souza G, Shetty PS, Calder AG, et al.. Whole body protein metabolism in human pulmonary tuberculosis and undernutrition: evidence for anabolic block in tuberculosis. Clin Sci (Lond). 1998;94(3):321–31. Epub 1998/06/09. 10.1042/cs0940321 .
- de Pee S, Grede N, Mehra D, Bloem MW. The enabling effect of food assistance in improving adherence and/or treatment completion for antiretroviral therapy and tuberculosis treatment: a literature review. AIDS Behav. 2014;18 Suppl 5:S531–41. Epub 2014/03/13. 10.1007/s10461-014-0730-2 .
- FAO I UNICEF, WFP WHO. The State of Food Security and Nutrition in the World. Rome: FAO, 2019.
- WHO. World Health statistics. 2019.
- WHO. World Health statistics. 2013.
- Perez-Guzman C, Vargas MH, Quinonez F, Bazavilvazo N, Aguilar A. A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest. 2005;127(2):643–51. Epub 2005/02/12. 10.1378/chest.127.2.643 .
- Martins N, Morris P, Kelly PM. Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste. BMJ. 2009;339:b4248. Epub 2009/10/28. 10.1136/bmj.b4248
- Jahnavi G, Sudha CH. Randomised controlled trial of food supplements in patients with newly diagnosed tuberculosis and wasting. Singapore Med J. 2010;51(12):957–62. Epub 2011/01/12. .
- Sudarsanam TD, John J, Kang G, Mahendri V, Gerrior J, Franciosa M, et al.. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV-tuberculosis coinfection receiving directly observed short-course chemotherapy for tuberculosis. Trop Med Int Health. 2011;16(6):699–706. Epub 2011/03/23. 10.1111/j.1365-3156.2011.02761.x
- Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev. 2016;(6):CD006086. Epub 2016/06/30. 10.1002/14651858.CD006086.pub4
Source: PubMed